Pomalidomide - Celgene Corporation
Alternative Names: Actimid; CC-4047; CDC-394; Imnovid; Pomalidomide-Celgene; PomalystLatest Information Update: 15 Jan 2024
At a glance
- Originator Celgene Corporation
- Developer Bristol-Myers Squibb; Celgene Corporation; Dana-Farber Cancer Institute; Sarah Cannon Research Institute; University of Texas M. D. Anderson Cancer Center
- Class Anti-inflammatories; Antianaemics; Antineoplastics; Phthalimides; Piperidones; Skin disorder therapies; Small molecules
- Mechanism of Action Angiogenesis inhibitors; Apoptosis stimulants; Interleukin 6 inhibitors; Natural killer cell stimulants; T lymphocyte stimulants; Tumour necrosis factor alpha inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Kaposi's sarcoma; Multiple myeloma
- Phase III Myelofibrosis
- Phase II Brain cancer; Systemic scleroderma
- Phase I/II Amyloid light-chain amyloidosis
- No development reported Pancreatic cancer; Sickle cell anaemia; Small cell lung cancer; Waldenstrom's macroglobulinaemia
Most Recent Events
- 10 Jan 2024 Janssen terminates a phase II trial in Multiple-myeloma in (Combination therapy, Second-line or greater therapy) in USA due to low accrual (NCT04700176)
- 01 Nov 2023 Celgene terminates a phase II trials in Multiple myeloma (Second-line therapy or greater, Combination therapy) in USA (PO) due to lack of enrollment (NCT02188368)
- 14 Sep 2023 Celgene completes a phase II trial in Brain cancer (In adolescents, In children, In infants, Monotherapy, Recurrent, Second-line therapy or greater, In adults) in USA, France, Spain, United Kingdom and Italy (PO) (NCT03257631) (EudraCT2016-002903-25)